The Trump administration has decided not to allow Medicare to cover obesity drugs, a decision that would have provided millions of older Americans access to these medications but cost the government billions of dollars. This highly anticipated move led to a decline in stock prices of obesity drug manufacturers such as Eli Lilly & Co. and Novo Nordisk A/S.
— new from Bloomberg.com
